anti-Nipah_156
| anti-Nipah_ID | anti-Nipah_156 |
| anti-Nipah Drug | AAHL 33 |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | M17 |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.25 MOI |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Pre infection |
| Duration of Drug delivery for anti-Nipah activity | 18 hours |
| Drug concentration used to test anti-Nipah activity | 4.188 μM |
| Assays used to test anti-Nipah activity | Chemiluminescent |
| anti-Nipah activity | Decrease [Inhibitory concentration (50 %)] |
| References | Aljofan M, Saubern S, Meyer AG, Marsh G, Meers J, Mungall BA. Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. Virus Res. 2009 Jun;142(1-2):92-9. doi: 10.1016/j.virusres.2009.01.014. |
| Comments | Comparison of a panel of 54 novel antiviral compounds identified during routine screening of an in-house compound library in Vero, BHK-21 and BSR cells suggests no clear advantage of screening in either cell type. |